Poor
Mostly Unaligned
Patient Risk:
Low
Summary
Most claims concern pricing and out-of-pocket cost and are absent from the provided FDA label sections; only the general existence of a dosage/administration section is shown, with insufficient extracted text to confirm the specific dosing/route wording.
Category Scores
Accurate Statements
Prolia (denosumab) is given as a subcutaneous injection once every 6 months.
Partially supported only in the sense that a 'DOSAGE AND ADMINISTRATION' section is present in the provided label sections; extracted label text is insufficient to confirm exact wording for route ('subcutaneous') and interval ('once every 6 months').
Unsupported Statements
Prolia is typically priced on a per-dose basis.
Not supported by the provided FDA label sections (sections available: only 1 INDICATIONS AND USAGE and 2 DOSAGE AND ADMINISTRATION).
The exact out-of-pocket cost depends on insurance coverage, pharmacy price, and whether a manufacturer program is used.
Not supported by the provided FDA label sections.
Without insurance, patients often pay the full pharmacy price for the dose, plus any dispensing fees charged by the pharmacy.
Not supported by the provided FDA label sections.
Pharmacy pricing changes frequently.
Not supported by the provided FDA label sections.
The only reliable way to estimate your cost is to check the cash price at your pharmacy (or a price comparison tool), dose strength and exact product, and any clinic-administered markup if the injection is given in a doctor’s office.
Not supported by the provided FDA label sections.
Your final cost commonly depends on whether you have commercial insurance vs. Medicare vs. Medicaid.
Not supported by the provided FDA label sections.
Your final cost commonly depends on your specific copay/coinsurance terms.
Not supported by the provided FDA label sections.
Your final cost commonly depends on whether Prolia is billed as a pharmacy benefit or a medical benefit.
Not supported by the provided FDA label sections.
Your final cost commonly depends on eligibility for any patient assistance or savings programs.
Not supported by the provided FDA label sections.
If the injection is billed under a medical benefit at a clinic, your cost may include clinic administration charges in addition to the drug cost.
Not supported by the provided FDA label sections.
If you obtain Prolia through a pharmacy, you will usually see a pharmacy copay instead.
Not supported by the provided FDA label sections.
Different billing pathways can produce different out-of-pocket amounts even for the same dose.
Not supported by the provided FDA label sections.
Contradictions
Important Omissions
No FDA label content related to boxed warnings, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, storage/handling, or administration instructions (beyond the single partially-adjacent dosing/route claim) is assessed or included in the evaluated response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are primarily about cost and billing rather than safety-critical clinical directions. However, the only dosing-related claim is not fully confirmable from the provided label excerpt, so label fidelity for administration details cannot be verified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Unaligned
Primary Issue
Majority of statements are about pricing/out-of-pocket costs and are absent from the provided FDA label sections; dosing/administration specifics are only partially supported and not confirmable from the extracted label text provided.
Suggested Improvement
Remove or reframe all pricing/cost/billing/manufacturer-program/copay/benefit-pathway claims unless corresponding FDA label text is provided; ensure dosing/route/interval wording is directly supported by the actual FDA label '2 DOSAGE AND ADMINISTRATION' text.